Literature DB >> 9527774

Influence of renal failure on ciprofloxacin pharmacokinetics in rats.

B Nouaille-Degorce1, C Veau, S Dautrey, M Tod, D Laouari, C Carbon, R Farinotti.   

Abstract

Ciprofloxacin pharmacokinetics have been shown to be modified in patients with renal failure (e.g., the intestinal secretion of ciprofloxacin is increased). This study investigated the influence of renal failure on the pharmacokinetics of ciprofloxacin following oral and parenteral administration to rats of a dose of 50 mg/kg of body weight. After parenteral administration, only renal clearance (CLR) was reduced in nephrectomized rats (5.3+/-1.4 versus 17.8+/-4.7 ml/min/kg, P < 0.01, nephrectomized versus control rats). However, nonrenal clearance was increased in nephrectomized rats (32+/-4 versus 15+/-5 ml/min/kg, P < 0.01, nephrectomized versus control rats), suggesting compensatory mechanisms for reduced renal function. After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter). Terminal elimination half lives in the two groups remained constant after oral and parenteral administration. These results suggest an increased bioavailability of ciprofloxacin in nephrectomized rats, which was confirmed by a nonlinear mixed-effect model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527774      PMCID: PMC105402          DOI: 10.1128/AAC.42.2.289

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.

Authors:  G L Drusano; M Weir; A Forrest; K Plaisance; T Emm; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

2.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.

Authors:  F Mentré; R Gomeni
Journal:  J Biopharm Stat       Date:  1995-07       Impact factor: 1.051

Review 3.  Effect of renal failure on drug metabolism by the liver.

Authors:  A C Elston; M K Bayliss; G R Park
Journal:  Br J Anaesth       Date:  1993-08       Impact factor: 9.166

4.  Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.

Authors:  G Bianchetti; G Graziani; D Brancaccio; A Morganti; G Leonetti; M Manfrin; R Sega; R Gomeni; C Ponticelli; P L Morselli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

5.  Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient.

Authors:  T P Gibson; K M Giacomini; W A Briggs; W Whitman; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

6.  Glomerular response to acute protein load is not blunted by high-protein diet or nephron reduction.

Authors:  M Burtin; D Laouari; C Kindermans; C Kleinknecht
Journal:  Am J Physiol       Date:  1994-05

7.  Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.

Authors:  T C Gasser; S C Ebert; P H Graversen; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

8.  Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.

Authors:  E Singlas; A M Taburet; I Landru; H Albin; J P Ryckelinck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.

Authors:  H M Siefert; D Maruhn; W Maul; D Förster; W Ritter
Journal:  Arzneimittelforschung       Date:  1986-10

10.  Pharmacokinetics of intravenously administered ciprofloxacin in intensive care patients with acute renal failure.

Authors:  M S Dirksen; T B Vree
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
View more
  7 in total

1.  Influence of renal failure on intestinal clearance of ciprofloxacin in rats.

Authors:  S Dautrey; L Rabbaa; D Laouari; B Lacour; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

2.  Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Authors:  Ken-ichi Umehara; Gian Camenisch
Journal:  Pharm Res       Date:  2011-10-20       Impact factor: 4.200

3.  Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment.

Authors:  Y H Hwang; M S Kim; I B Song; J H Lim; B K Park; H I Yun
Journal:  Vet Res Commun       Date:  2008-12-16       Impact factor: 2.459

4.  Transcutaneous sampling of ciprofloxacin and 8-methoxypsoralen by electroporation (ETS technique).

Authors:  Srinivasa M Sammeta; Siva Ram K Vaka; S Narasimha Murthy
Journal:  Int J Pharm       Date:  2008-11-05       Impact factor: 5.875

5.  Preparation and evaluation of enrofloxacin microspheres and tissue distribution in rats.

Authors:  Fan Yang; Jijun Kang; Fang Yang; Zhensheng Zhao; Tao Kong; Zhenling Zeng
Journal:  J Vet Sci       Date:  2015-01-30       Impact factor: 1.672

6.  Effects of berberine and hwangryunhaedok-tang on oral bioavailability and pharmacokinetics of ciprofloxacin in rats.

Authors:  Youn-Hwan Hwang; Won-Kyung Cho; Doorye Jang; Jeong-Ho Ha; Kiyoun Jung; Hyo-In Yun; Jin Yeul Ma
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

Review 7.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.